Ganga Pharma's FY26 results show modest uptick, no surprises
Revenue rose to ₹282.79 lakhs, net profit to ₹10.15 lakhs; clean audit opinion keeps the filing routine for the nano-cap.
— 1 earlier story on Ganga Pharmaceuticals Ltd. → ₹10.15 lakhs Net profit for FY26, up from ₹7.90 lakhs
What's new
- Revenue inched up to ₹282.79 lakhs from ₹263.74 lakhs
- Net profit rose 28% to ₹10.15 lakhs from ₹7.90 lakhs
- Auditor issued an unmodified opinion; no profit warnings or guidance changes
Why it matters
For a nano-cap with a ₹7 crore market cap, these are routine results that carry no market-moving news. The modest improvement and clean audit provide no reason for material share price action.
What we're watching
- Next quarter's revenue trajectory to see if growth sustains
- Any future guidance from management on scaling operations
The full read
Ganga Pharmaceuticals reported a modest uptick in its audited FY26 numbers. Revenue inched up to ₹282.79 lakhs and net profit to ₹10.15 lakhs, both marginally higher than the prior year. The auditor issued a clean opinion. For a company with a market cap just over ₹7 crore, the results are routine and contain no surprises that would move the stock.
Mentioned: FY26 audited results · ₹282.79 lakhs revenue · ₹10.15 lakhs net profit
Primary source BSE filings for GANGAPHARM NSE filings for GANGAPHARM Research GANGAPHARM on Tijori Finance Our reading is derived from the exchange filing. Verify on the exchange before acting.